<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The restoration of energy balance during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> is critical to cellular survival; however, relatively little is known concerning the regulation of neuronal metabolic pathways in response to central <z:mp ids='MP_0008912'>nervous</z:mp> system <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="47" ids="16027,28971">AMP</z:chebi>-activated protein kinase (AMPK), a master sensor of energy balance in peripheral tissues, is phosphorylated and activated when energy balance is low </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated whether AMPK might also modulate neuronal energy homeostasis during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We utilized two model systems of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in vivo and oxygen-<z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation in vitro, to delineate changes in AMPK activity incurred from a metabolic stress </plain></SENT>
<SENT sid="4" pm="."><plain>AMPK is highly expressed in cortical and hippocampal neurons under both <z:mpath ids='MPATH_458'>normal</z:mpath> and ischemic conditions </plain></SENT>
<SENT sid="5" pm="."><plain>AMPK activity, as assessed by phosphorylation status, is increased following both middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> and oxygen-<z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation </plain></SENT>
<SENT sid="6" pm="."><plain>Pharmacological inhibition of AMPK by either C75, a known modulator of neuronal ATP levels, or compound C reduced <z:hpo ids='HP_0001297'>stroke</z:hpo> damage </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, activation of AMPK by 5-<z:chebi fb="0" ids="22512">aminoimidazole</z:chebi>-4-<z:chebi fb="0" ids="23004,37622">carboxamide</z:chebi> <z:chebi fb="0" ids="18254">ribonucleoside</z:chebi> exacerbated damage </plain></SENT>
<SENT sid="8" pm="."><plain>Mice deficient in neuronal nitric-<z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase demonstrated a decrease in both <z:hpo ids='HP_0001297'>stroke</z:hpo> damage and AMPK activation compared with <z:mp ids='MP_0002169'>wild type</z:mp>, suggesting a possible interaction between NO and AMPK activation in <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>These data demonstrate a role for AMPK in the response of neurons during metabolic stress and suggest that in <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> the activation of AMPK is deleterious </plain></SENT>
<SENT sid="10" pm="."><plain>The ability to manipulate pharmacologically neuronal energy balance during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> represents an innovative approach to neuroprotection </plain></SENT>
</text></document>